ArticleAmerican journal of translational research2026
Edoxaban plus aspirin de-escalation strategy versus continuous dual antithrombotic therapy in the perioperative period for patients with atrial fibrillation undergoing carotid artery stenting: a retrospective cohort study.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare the safety and efficacy of an edoxaban-based, time-limited dual antithrombotic therapy followed by a de-escalation strategy versus a continuous dual antithrombotic strategy in patients with atrial fibrillation (AF) undergoing carotid artery stenting (CAS).
methodsA total of 120 patients with CAS and AF who underwent surgery at Guizhou Panjiang Investment Holding (Group) Co., Ltd. General Hospital from June 2023 to December 2024 were retrospectively enrolled. According to the perioperative antithrombotic regimen, patients were divided into a de-escalation group (n=56) and a dual therapy group (n=64). Patients in the de-escalation group received edoxaban (standard dose) combined with aspirin (100 mg/d) preoperatively and during the first 6 months postoperatively, after which aspirin was discontinued and edoxaban monotherapy was continued from 6 to 12 months postoperatively. Patients in the dual therapy group received continuous treatment with edoxaban plus aspirin throughout the 12-month follow-up period. Platelet count, C-reactive protein (CRP), D-dimer, fibrinogen, and coagulation parameters, including prothrombin time (PT), thrombin time (TT), and activated partial thromboplastin time (APTT), were compared at 1, 6, and 12 months postoperatively. Bleeding events, embolic events, adverse reactions, carotid artery restenosis, stent thrombosis, health-related quality of life (EQ-5D-5L), and treatment adherence were recorded.
resultsBaseline characteristics were comparable between the two groups. After treatment, platelet count, CRP, D-dimer, and fibrinogen levels significantly decreased, whereas PT, TT, and APTT were significantly prolonged in both groups, with no significant intergroup differences. There was no significant difference in the incidence of vascular restenosis or stent thrombosis between the two groups (
conclusionIn patients with AF undergoing CAS, an edoxaban-based de-escalation strategy involving conversion to monotherapy at 6 months postoperatively was non-inferior to continuous dual antithrombotic therapy in preventing ischemic events. This strategy significantly reduced bleeding risk at 12 months postoperatively and improved quality of life and treatment adherence, representing a safe and effective perioperative antithrombotic management regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.